Analysts Set Bicycle Therapeutics plc (NASDAQ:BCYC) Target Price at $25.00

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have received an average rating of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $25.00.

Several equities analysts recently issued reports on the company. JMP Securities reduced their price target on Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a research report on Friday, May 2nd. Barclays reduced their price target on Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Morgan Stanley set a $17.00 price target on Bicycle Therapeutics and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Needham & Company LLC restated a "buy" rating and set a $29.00 price target on shares of Bicycle Therapeutics in a research report on Friday, May 2nd. Finally, Royal Bank of Canada reduced their price target on Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its stake in shares of Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock valued at $191,000 after purchasing an additional 1,782 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Bicycle Therapeutics by 30.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock valued at $131,000 after purchasing an additional 2,191 shares in the last quarter. Barclays PLC boosted its stake in shares of Bicycle Therapeutics by 878.3% during the 4th quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after purchasing an additional 2,345 shares in the last quarter. Tocqueville Asset Management L.P. boosted its stake in shares of Bicycle Therapeutics by 24.5% during the 1st quarter. Tocqueville Asset Management L.P. now owns 18,300 shares of the company's stock valued at $155,000 after purchasing an additional 3,600 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Bicycle Therapeutics by 18.9% during the fourth quarter. Jane Street Group LLC now owns 23,991 shares of the company's stock valued at $336,000 after purchasing an additional 3,811 shares in the last quarter. Institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Stock Performance

NASDAQ:BCYC traded down $0.12 during trading hours on Thursday, reaching $8.51. The company's stock had a trading volume of 237,186 shares, compared to its average volume of 405,001. The firm has a market capitalization of $589.35 million, a price-to-earnings ratio of -2.59 and a beta of 1.60. The firm has a 50-day simple moving average of $8.18 and a 200-day simple moving average of $12.99. Bicycle Therapeutics has a 1 year low of $6.10 and a 1 year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business had revenue of $9.98 million during the quarter, compared to analysts' expectations of $8.67 million. Equities analysts anticipate that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.